Skip to content

To evaluate the Safety and medicinal effectiveness of Unani formulations SafÅ«f Patthar Phori and Sharbat BazÅ«ri Muâ??tadil in HasÄ?h al-Kulya (Nephrolithiasis)

Clinical Validation of Unani Pharmocopoeial Formulations â?? SafÅ«f Patthar Phori and Sharbat BazÅ«ri Muâ??tadil in HasÄ?h al-Kulya (Nephrolithiasis)

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2015/10/006272
Enrollment
300
Registered
2015-10-19
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N200- Calculus of kidney Health Condition 2: null- HasÄ?h al-Kulya (Nephrolithiasis)

Interventions

Intervention1: SafÅ«f Patthar Phori and Sharbat BazÅ«ri Muâ??tadil: SafÅ«f Patthar Phori: 3 gm BD orally to be taken with water after meals Sharbat BazÅ«ri Muâ??tadil: 25 ml BD orally to be taken wit

Sponsors

Central Council for Research in Unani Medicine New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • Patients of either sex with 18-60 years of age • Patients with HasÄ?h al-Kulya (nephrolithiasis) as diagnosed by X-Ray/Ultrasound KUB with calculi measuring ï?§ Bawl al-Dam(Hematuria) ï?§ Siql al-KhÄ?sira (Heaviness in the Loin) ï?§ Wajaâ?? al-KhÄ?sira (Pain in the Loin) ï?§ History of Recurrent UTI ï?§ History of Recurrent Nephrolithiasis ï?§ Urine showing Calcium Crystalluria

Exclusion criteria

Exclusion criteria: • Patients having acute condition of nephrolithiasis • Complicated cases of nephrolithiasis requiring surgical intervention • Patients with hydronephrosis, acute symptoms of UTI or any other renal diseases • Patients with eGFR • Patients on long-term medications • Patients with cardiac, pulmonary or hepatic diseases • Pregnancy and lactation • Alcohol or drug abuse/ History of alcohol or drug abuse within 6 mo prior to baseline

Design outcomes

Primary

MeasureTime frame
Improvement in signs and symptoms of HasÄ?h al-Kulya (Nephrolithiasis)Timepoint: 8 weeks

Secondary

MeasureTime frame
Haematological and biochemical assessments for safety ï?· Improvement in the feeling of well-being of the patientTimepoint: 8 weeks

Countries

India

Contacts

Public ContactDR PRADEEP KUMAR

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@gmail.com9810161758

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026